2023 Boston Pharmaceutical Symposium

The Boston Chapter first organized the Boston Pharmaceutical Symposium in 2017. Since then, the symposium has become a very successful annual event. The Boston Pharmaceutical Symposium provides a unique venue for sharing statistical applications and research in the biotech-pharma industry, and building connections among all colleagues of the Greater Boston area engaged in statistical practice. We welcome the participation from industry statisticians, academia researchers, university students, and any professionals interested in pharmaceutical statistical topics.

The 2023 Boston Pharmaceutical Symposium will be held at Sanofi’s Campus, in Cambridge MA on October 13, 2023. It’s going to be a full-day event, featuring invited talks, a poster session, network opportunities, and much more. 

All participants in the symposium must register by Friday, October 6. The registration fee covers a light breakfast, lunch, afternoon snacks, and symposium materials. 

Please note: Valid photo ID is required at registration and must be presented to the Sanofi security. Requirements to enter Sanofi buildings are subject to change.

Note to poster presenters: all presenters are expected to register for the symposium and are responsible for printing and transport of the poster. For additional information, please contact ASA.Boston.Pharm.Symposium@gmail.com.

Register Here!

Our speakers

Keynote speakers:

• From Traditional Statistics to AI for Clinical Trials and Beyond - A Paradigm Shift by Mark Chang, Founder, Adjunct Professor, AGInception, Boston University

• Strategic Innovations in Clinical Development: Unpacking the Statistical Team's Significance by Sammi Tang, Global Head of Biometrics, Co-founder of DahShu, Servier

Invited speakers:

• A multi-arm two-stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trials by Gu Mi, Director, Senior Statistical Project Lead, Sanofi

• Optimization of Graphic Multiple Comparison Procedures in Confirmatory Trials by George Kong/Ting Wang, Director, Biostatistics/Sr. Principal Biostatistician, Biogen

• Master Protocols in a Pandemic: A Case Study in Statistical Leadership by Lisa LaVange, Professor and Former Chair, Department of Biostatistics, UNC – Chapel Hill

• Hybrid platform trial incorporating external data by Wei Wei, Senior manager, Statistics, Takeda

• Marginal versus conditional rate estimation for count and recurrent event data with an estimand framework by Sarah Conner, Real World Principal Biostatistician, Vertex

• How large-scale simulation is reshaping clinical development strategy: an insider’s guide by Yannis Jemiai, Chief Scientific Officer, Cytel

• Enriching Real-World Data Based Studies by Conducting Linkage among Multiple Data Sources by Tianyu Sun, Manager, Real-World Evidence Analytics, Moderna